NewLeaf Symbiotics Receives Key US Production Patent

Invention allows cost efficient large-scale product fermentation

The US Patent and Trademark Office has granted NewLeaf Symbiotics US Patent No. 9,181,541 for its Microbial Fermentation technology.  The patent covers compositions comprising Pink Pigmented Facultative Methylotrophs (PPFMs).  PPFMs are beneficial bacteria that naturally colonize plants and stimulate their growth.

NewLeaf is developing and commercializing products that contain PPFMs and other bacteria.  PPFMs will need to be fermented in vast numbers to fill demand for new and sustainable agricultural inputs.  The patent discloses a breakthrough invention made by NewLeaf at its Bio Research & Development Growth (BRDG) Park labs that allow the company to produce these bacteria many times more efficiently than was possible in the past.

"This US patent is foundational for us. It is now clear that to meet demand for products we are planning to introduce in 2016, and those in the pipeline, we are going to require large-scale fermentation of PPFM strains."

Tom Laurita, CEO of NewLeaf

NewLeaf chief scientist Gregg Bogosian made the invention in 2012.  “NewLeaf Symbiotics needed to produce large quantities of PPFMs in a cost efficient manner when previously only small amounts had been made,” said Bogosian. “We faced a field trial deadline and could not possibly have met it unless we could increase production rates by several factors. This proprietary technology allowed us to quickly produce the required quantities, and we now use it in all production contexts.”

“This US patent is foundational for us,” stated Tom Laurita, CEO of NewLeaf. "It is now clear that to meet demand for products we are planning to introduce in 2016, and those in the pipeline, we are going to require large-scale fermentation of PPFM strains.  Patenting this invention means three things for NewLeaf.  First, we have already seen that the method allows us to reach the scale we need.  Second, this production technology puts us in a very attractive COGS position.  Third, others would be discouraged from trying to compete in this space because the new method is so far superior to alternatives.”

NewLeaf is highly focused on the development of a strong portfolio of intellectual property, working closely with its IP partners Thompson Coburn LLP and McKee, Voorhees, & Sease PLC.  The Company has filed over 25 patents that cover a broad range of applications including methods of production and formulation, crop yield enhancement, and activity against pathogens and pests.

About NewLeaf Symbiotics
NewLeaf Symbiotics is a venture-funded, non-GMO agricultural biologicals company engaged in discovery, development, production, and commercialization of products containing beneficial plant bacteria.  Its 30+member team is based in BRDG Park at the Donald Danforth Plant Science Center in St Louis, Missouri.  Visit NewLeaf Symbiotics at

About BRDG Park at the Danforth Center
Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center helps life science companies bridge research, resources and relationships to achieve commercial success. In addition to providing world-class wet laboratories, office space and a prominent incubator, BRDG Park’s location on the Danforth Center’s campus facilitates access to the intellectual capital of top scientists, as well as to greenhouses, growth chambers, microscopy and proteomics facilities and other vital resources. Located in suburban St. Louis County, Missouri, BRDG Park is being developed by Wexford Science +Technology LLC, a BioMed Realty Company, a development company led by a seasoned team of real estate, finance and engineering experts specializing in major university facilities and science research parks nationwide. More information is available at